Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos


FEATUREDASCO SEP DigitalLearn from 22 peer-reviewed chapters and 90 self-assessment questions with answer rationales and references. Meetings ASCO Annual Meeting Best of ASCO ASCO Breakthrough Global Summit ASCO Quality Care Symposium ASCO Gastrointestinal Cancers Symposium ASCO Genitourinary Cancers Symposium Multidisciplinary Head & Neck Symposium Multidisciplinary Thoracic Cancers...

  • 123456 Profile photo of Madelyn

    Rusfertide is a novel therapeutic option for patients with ET. Many patients with ET are phlebotomy dependent to reduce of thrombosis risk. Rusfertide is exciting because it is a hepcidin memetic that can lower the hematocrit without effects on other blood counts and without causing iron deficiency. #ASCO22 #MPNs